From fundamental research to clinical development, the in-house efforts made by Ipsen’s R&D department are supported by an active partnerships policy.
An active partnerships policy
The in-house efforts made by Ipsen’s R&D department are supported by an active partnerships policy, managed by the Scientific Affairs team, from the fundamental research stage right through to clinical development.
Our philosophy in this respect is based on the knowledge that even though Ipsen’s R&D employees are leading experts in their fields, they represent only a tiny fraction of the expertise available in our specialist fields around the world. It is therefore essential to combine internal skills and projects with those of other leading actors in medical and pharmaceutical R&D.
Several academic partnerships
At the research stage, the Group has set up academic collaborations with Massachusetts General Hospital, the Dana-Farber Cancer Institute and the Harvard Medical School in Boston, Biostar in Singapore, and Inserm in France.
Since 2008, the Group has been a long-term partner with the prestigious Salk Institute (La California), which has conducted fundamental research in the Group’s subjects of interest. Partnerships have also been established with pioneering biotech companies, offering access to innovative and promising technology to discover potential new drugs.